8-K current report · filed Oct 5, 2026

Rezolute, Inc. (RZLT) 8-K Current Report: October 5, 2026

Item 7.01Item EX-99.1RZLT overview

Short answer

Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FDA discussions on Rezolute’s sunRIZE trial signal potential changes to the program’s regulatory path.

Rezolute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA discussions on Rezolute’s sunRIZE trial signal potential changes to the program’s regulatory path
  • Next steps remain under discussion, creating uncertainty around trial timing and development milestones
  • Investors should review Exhibit 99.1 for the substantive FDA update and any implications for sunRIZE
  • Forward-looking statements carry execution and regulatory risks, with no obligation to provide future updates

Item EX-99.1 · Exhibit EX-99.1

  • FDA recommended a Type B pre-BLA meeting for congenital HI, advancing ersodetug toward potential BLA submission
  • sunRIZE missed its primary and key secondary endpoints, leaving approval prospects uncertain despite observed CGM-based improvements
  • FDA made no approvability determination, with potential additional randomized trial requirements creating timing and cost risk
  • Topline Phase 3 upLIFT results in tumor HI expected this quarter, potentially shaping a combined BLA strategy
  • Open-label sunRIZE extension shows treatment duration from approximately nine months to over two years with continued glycemic control signals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Rezolute, Inc. 8-K filings

Get the next RZLT 8-K as it lands

Follow RZLT for push alerts, or ask the research agent what this filing means.